New immune cell therapy shows promise for Tough-to-Treat colon cancer
Disease control
Completed
This study tested a new immunotherapy called STIMVAX in 29 adults with metastatic colorectal cancer that had not responded to two prior treatments. STIMVAX uses immune cells from healthy donors to help the body fight cancer. The main goals were to see how long patients lived and …
Phase: PHASE2 • Sponsor: Mirror Biologics, Inc. • Aim: Disease control
Last updated May 03, 2026 01:42 UTC